Media 280723

CTO Mr Craig Weller said on Aqua Phase studies revealing the absorption of CBD as more than 4 times greater than CBD in oil:
Bod has been sweating on the PK study for months. It needed to show improved bioavailability of 30% for the deal to proceed, it exceeded by a factor of 10, what this means is that if we ingest 100mg of CBD in oil, we will normally absorb 6-8% of the dose. With Aqua Phase, the CBD absorption is 32% This means we can either get a better response to the CBD or otherwise we can reduce the Aqua Phase dose – giving potentially less side effects and providing CBD raw material savings.
ASX Health Stocks: Pot stock BOD’s Phase 1 results; Paradigm and Impedimed shake up exec teams
22 Nov 2022
Published by: Stockhead
Company news: Releaf Group; Bod; Wellnex Life; MGC Pharma; MediCann Health
27 Oct 2022
Published by: Cannabiz
Weed and gold, the unloved investment thematics
22 Oct 2022
Published by: Next Investors
Company news: Bod; Incannex; Medlab; Rua Bioscience; Emyria
20 Oct 2022
Published by: Cannabiz
Bod set to launch CBG isolate via Special Access Scheme this month
19 Oct 2022
Published by: Cannabiz
Bod spies ‘enormous potential’ of technology acquisition as pressure grows to generate revenue
13 Oct 2022
Published by: Cannabiz
What Investors Should Know About Australia’s New CBD Rules
02 Feb 2022
Published by: Investing News Network
Company news: Bod Australia; Cann Group; MediCann Health; MGC Pharma; Wellnex Life
05 Oct 2022
Published by: Cannabiz